权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Translational Approaches to Mitigate Enhanced Alzheimer’s Disease Risk Following a Mild TBI

减轻轻度 TBI 后阿尔茨海默病风险增加的转化方法

基本信息

批准号：
10090757
负责人：
ADAM D BACHSTETTER
金额：
$ 114.75万
依托单位：
UNIVERSITY OF KENTUCKY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-04-01 至 2024-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10090757
关键词：
APP-PS1 Acids Address Adult Affinity Age Agonist Agreement Alzheimer&apos s Disease Alzheimer&apos s disease risk Amyloid beta-Protein Assisted Living Facilities Binding Bioenergetics Blood - brain barrier anatomy Brain Bypass Caloric Restriction Chronic Clinical Closed head injuries Cognitive Cognitive deficits Complex Data Dementia Development Disease Dose Elderly Electron Transport Energy Metabolism Environmental Risk Factor Epidemiology Exercise Experimental Designs Exposure to FDA approved Family member Fasting G-Protein-Coupled Receptors Goals Head Implant Incidence Independent Living Individual Inflammasome Inflammation Injury Interleukin-1 beta Intervention Ketone Bodies Ketones Knock-in Mouse Knockout Mice Life Liver Measures Microglia Mitochondria Mus Neurodegenerative Disorders Neurologic Nicotinic Acids Odds Ratio Oral Pathologic Pathology Persons Pharmaceutical Preparations Population Populations at Risk Positron-Emission Tomography Property Pump Radiology Specialty Receptor Activation Recovery Reporting Risk Risk Factors Societies Starvation System TBI treatment Testing Therapeutic Time Traumatic Brain Injury Work beta amyloid pathology beta-Hydroxybutyrate brain health design efficacious intervention experience experimental study falls human old age (65+)immunoregulation ketogenic diet loss of function loved ones medical attention member mild traumatic brain injury mitochondrial dysfunction modifiable risk mouse model multi-component intervention neurodegenerative dementia neuroinflammation pre-clinical prevent receptor subcutaneous translational approach young adult β-amyloid burden

项目摘要

ABSTRACT A traumatic brain injury (TBI) is a well-known risk factor for Alzheimer's disease. There is not a one-to-one relationship, where a TBI will lead to the development of Alzheimer's disease. The lack of a direct connection suggests a selective vulnerability. Problematically, when a person has a mild TBI, it is not possible to know if they will recover without an impact on their brain health or if they have now increased their vulnerability to developing Alzheimer's disease. What can be done? One approach is a broad administration of therapy shortly after the injury. Since this approach requires treating some people who would recover from the TBI without intervention, the benefit-to-risk ratio must be very high. That is, you do not want to cause harm by giving an unneeded drug. Our long-term goal is to identify safe treatments to be used after a mild TBI in an older adult population to lessen the chance of developing Alzheimer's disease. There are currently no FDA approved drugs to be used after a mild TBI to reduce secondary injury mechanisms. We believe that not treating after a mild TBI is a missed opportunity, but the treatment needs to be safe. Our preliminary evidence shows that a TBI causes deficits in energy metabolism and increased neuroinflammation, both of which are exacerbated by preexisting proteinopathies, such as amyloid-beta. To target these mechanisms, we have identified Beta- hydroxybutyrate (BHB; 3-hydroxybutyric acid) as a safe multimodal intervention. BHB is a ketone body, which is continuously produced by the liver at low levels but can rise above 1mM during periods of fasting, calorie restriction, prolonged exercise, or by the ketogenic diet. Clinically, BHB is safe to be administered orally, BHB rapidly crosses the blood-brain-barrier, and in cases of starvation, ketones can provide as much as 70% of the brain's energy. BHB is an alternative biofuel, that can bypass blockages in the electron transport system caused by amyloid-beta, and TBI, which decrease mitochondrial bioenergetics. BHB has also been shown to suppress inflammation via an inflammasome-dependent mechanism and by binding to a recently deorphanized GPCR called HCA2. We will test the central hypothesis that BHB will be effective at reducing functional deficits seen in APP/PS1 KI mice following a mild TBI through both energetic and neuroinflammatory dependent mechanisms, in three specific aims (SA). SA1: Dose-dependent effects of BHB on mitochondrial function and neuroinflammation after TBI. SA2: Define the immunomodulatory properties of the HCA2 receptor, via dose-dependent effects of niacin, a high-affinity HCA2 agonist. SA3: Define the immunomodulatory properties BHB through the HCA2 receptor through loss of function experiment. Our work seeks to address the mechanisms associated with the increased fragility of the older brain which keeps it from recovering from a mild TBI. We also will define the therapeutic potential of the BHB/HCA2 axis as a post-TBI neuroprotective strategy for use in a population at risk for Alzheimer's disease.

摘要